FDA-Approved Pill Blocks Allergy Attacks

Colorful pills and a rainbow ribbon on a pink background

An old asthma pill nearly wiped out deadly food allergy reactions in mice, hinting at a game-changing shield against hidden kitchen killers.

Story Snapshot

Northwestern Medicine discovers DPEP1 gene driving gut-based anaphylaxis via leukotrienes.
FDA-approved Zileuton blocks this pathway, eliminating allergic responses in preclinical tests.
Offers on-demand oral protection for accidental exposures, unlike desensitization therapies.
Builds on omalizumab’s 2024 FDA approval for multiple food allergies.
Impacts 32 million Americans, slashing $25 billion annual costs from ER visits.

Northwestern Breakthrough Identifies New Anaphylaxis Pathway

Laura Hoyt led Northwestern Medicine researchers in a years-long genetic screen on mice. They pinpointed DPEP1, a gene regulating leukotrienes in the gut that trigger anaphylaxis during food allergies. This pathway differs from traditional IgE mechanisms. Zileuton, an existing asthma drug, inhibited DPEP1 effectively. Mice pretreated with the pill showed near-complete blockade of reactions to various food allergens. Human trials remain pending, but results promise rapid translation.

Zileuton Repurposing Targets Accidental Exposures

Zileuton provides temporary protection without requiring allergen consumption, setting it apart from oral immunotherapies like Palforzia. Parents dread trace peanuts at parties or travel mishaps; this pill could preempt life-threatening episodes. Preclinical data demonstrated nearly eliminated responses, aligning with repurposing of proven drugs over risky new injectables. Facts support its potential as a practical safeguard.

Researchers position Zileuton for high-risk scenarios, such as school lunches or dining out. Unlike biologics needing refrigeration, an oral pill fits everyday carry. This approach echoes omalizumab’s shift from asthma, proving conservative drug recycling accelerates real-world benefits without endless trials.

Recent FDA Approvals Reshape Allergy Landscape

OUtMATCH trial propelled omalizumab (Xolair) to FDA approval in February 2024 for ages 1+, covering peanut, tree nuts, egg, milk, and wheat. Edwin Kim, Corinne Keet, and Mike Kulis at UNC drove these results, showing 67% reaction reduction versus placebo. Robert Wood’s Johns Hopkins study in March 2025 confirmed omalizumab outperforms OIT, minimizing side effects that plague desensitization.

Palforzia gained approval in 2020 for peanut OIT, but high dropout rates due to reactions persist. Omalizumab injectables protect against small exposures, enabling riskier eating. NIH-funded trials validate consistent efficacy across institutions.

Pipeline Advances in Antibodies and Vaccines

IgGenix’s IGNX001 entered Phase 1 in Australia around 2025, reporting positive safety for peanut antibodies. Derek Croote leads development. Aravax’s peanut vaccine advances in Phase 2 extension, with topline data due 2026 and Phase 3 planned. Sara Prickett oversees this T-cell targeting shot for long-term tolerance. FARE advocates push these innovations amid rising prevalence.

These injectables contrast Zileuton’s simplicity, but preclinical success bolsters leukotriene research, including ASU echoes. FDA’s Kelly Stone greenlit omalizumab, signaling openness to multi-food protections.

Implications Cut Emergency Costs and Fears

Short-term, treatments like omalizumab and potential Zileuton slash accidental reaction risks, freeing families from hyper-vigilance. Long-term, vaccines may enable sustained eating. Annual U.S. burden hits $25 billion in healthcare. Children gain normalcy at events, boosting quality of life without government overreach.

Industry expands biologics while challenging OIT dominance. Peer-reviewed evidence from Science and NEJM confirms no major conflicts, though FDA stresses omalizumab reduces—not eliminates—risks. Zileuton’s mouse data holds uniform promise.